KCNJ11 gene E23K variant and therapeutic response to sulfonylureas

European Journal of Internal Medicine

Volumn 23, Issue 3, 2012, Pages 245-249

  Javorsky, Martin ^a   Klimcakova, Lucia ^a   Schroner, Zbynek ^a   Zidzik, Jozef ^a   Babjakova, Eva ^a   Fabianova, Maria ^a   Kozarova, Miriam ^a   Tkacova, Ruzena ^a   Salagovic, Jan ^a   Tkac, Ivan ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

KCNJ11 E23K variant; Pharmacogenetics; Sulfonylurea; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE; GENOMIC DNA; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DRUG TARGETING; FEMALE; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACOGENETICS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84858749051     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.10.018     Document Type: Article

References (27)

1. A.G. Tabák, M. Jokela, T.N. Akbaraly, E.J. Brunner, M. Kivimäki, and D.R. Witte Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study Lancet 373 2009 2215 2221
2. D.M. Nathan, J.B. Buse, M.B. Davidson, G. Slama, B. Balkau, and P. Valensi Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
3. K. Zhou, L. Donnelly, L. Burch, R. Tavensdale, A.S. Doney, and G. Leese Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study Clin Pharmacol Ther 87 2010 52 56
4. E.R. Pearson, L.A. Donnelly, C. Kimber, A. Whitley, A.S. Doney, and M.I. McCarthy Variation in TCF7L2 influences therapeutic response to sulfonylureas. A GoDARTs study Diabetes 56 2007 2178 2182 (Pubitemid 47195841)
5. Z. Schroner, M. Javorsky, R. Tkacova, L. Klimcakova, M. Dobrikova, and V. Habalova Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes Diabetes Obes Metab 13 2011 89 91
6. F.M. Gribble, and F. Reimann Sulphonylurea action revisited: the post cloning era Diabetologia 46 2003 875 891 (Pubitemid 36961311)
7. S. Shyng, and C.G. Nichols Octameric stoichiometry of the KATP channel complex J Genet Physiol 110 1997 655 664 (Pubitemid 27524606)
8. F.M. Ashcroft, P. Proks, P.A. Smith, C. Ammälä, K. Bokvist, and P. Rorsman Stimulus-secretion coupling in pancreatic β-cells J Cell Biochem 55 1994 54 65 (Suppl)
9. A.L. Gloyn, M.N. Weedon, K.R. Owen, M.J. Turner, B.A. Knight, and G. Hitman Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that KCNJ11 E23K variant is associated with type 2 diabetes Diabetes 52 2003 568 572 (Pubitemid 36173218)
10. J.C. Florez, N. Burtt, P.I.W. de Bakker, P. Almgren, T. Tuomi, and J. Holmqvist Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region Diabetes 53 2004 1360 1368 (Pubitemid 38569024)
11. H. Inoue, J. Ferrer, M. Warren-Perry, Y. Zhang, R. Millns, and R.C. Turner Sequence variants in the pancreatic islet beta-cell inwardly rectifying K + channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM Diabetes 46 1997 502 507 (Pubitemid 27090282)
12. G. Sesti, E. Laratta, M. Cardellini, F. Andreozzi, S. Del Guerra, and C. Irace The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with increased risk of secondary failure to sulphonylurea in patients with type 2 diabetes J Clin Endocrinol Metab 91 2006 2334 2339 (Pubitemid 43855025)
13. + channel Diabetes 58 2009 2419 2424
14. A.L. Gloyn, Y. Hashim, S.J. Ashcroft, R. Ashfield, S. Wiltshire, and R.C. Turner Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53) Diabet Med 18 2001 206 212 (Pubitemid 32397858)
15. Y. Feng, G. Mao, X. Ren, H. Xing, G. Tang, and Q. Li Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients Diabetes Care 31 2008 1939 1944
16. H. Zhang, X. Liu, H. Kuang, R. Yi, and H. Xing Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes Diabetes Res Clin Pract 77 2007 58 61 (Pubitemid 46590477)
17. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 29 2006 S43 S48
18. A. Vella Pharmacogenetics for type 2 diabetes: practical considerations for study design J Diabetes Sci Technol 3 2009 705 709
19. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, and N.P. Jones Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443 (Pubitemid 44903747)
20. X. Sole, E. Guino, J. Valls, R. Iniesta, and V. Moreno SNPStats: a web tool for the analysis of association studies Bioinformatics 22 2006 1928 1929 (Pubitemid 44283043)
21. G. Salanti, L. Southam, D. Altshuler, K. Ardlie, I. Barroso, and M. Boehnke Underlying genetic models of inheritance in established type 2 diabetes associations Am J Epidemiol 170 2009 537 545
22. G. Schernthaner, A. Grimaldi, U. Di Mario, J. Drzewoski, P. Kempler, and M. Kvapil GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients Eur J Clin Invest 34 2004 535 542 (Pubitemid 39120222)
23. S. Bolen, L. Feldman, J. Vassy, L. Wilson, H.C. Yeh, and S. Marinpoulos Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 147 2007 386 399 (Pubitemid 351664540)
24. D. Sherifali, K. Nerenberg, E. Pullenayegum, J.E. Cheng, and H.C. Gerstein The effect of oral antidiabetic agents on A1C levels. A systematic review and meta-analysis Diabetes Care 33 2010 1859 1864
25. E.R. Pearson, I. Flechtner, P.R. Njølstad, M.T. Malecki, S.E. Flanagan, and B. Larkin Neonatal Diabetes International Collaborative Group: switching from insulin to oral sulphonylureas in patients with diabetes due to Kir6.2 mutations N Engl J Med 355 2006 467 477 (Pubitemid 44162274)
26. M. Rafiq, S.E. Flanagan, A.M. Patch, B.M. Shields, S. Ellard, and A.T. Hattersley The Neonatal Diabetes International Collaboration Group: effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations Diabetes Care 31 2008 204 209 (Pubitemid 351213320)
27. J. Stanik, D. Gasperikova, M. Paskova, L. Barak, J. Javorkova, and E. Jancova Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulphonylurea therapy in KCNJ11 and ABCC8 mutation carriers J Clin Endocrinol Metab 92 2007 1276 1282 (Pubitemid 46556398)